361 Capital’s Theravance Biopharma TBPH Stock Holding History

361 Capital’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$686K	Sell	32,680 -5,074	-13%	-$130K	0.32%	165
2020 Q1	$872K	Buy	+37,754	New	+$945K	0.4%	78
2019 Q4	–	Sell	-129,260	Closed	-$2.52M	–	395
2019 Q3	$2.52M	Buy	+129,260	New	+$2.61M	0.47%	89

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

361 Capital's TBPH Position: Q2 2020 in Review

361 Capital reduced its Theravance Biopharma (TBPH) stake by 13% in Q2 2020, selling an estimated $130K and leaving 32,680 shares worth $686K. The position accounts for 0.32% of the portfolio, ranked #165.

361 Capital first reported a position in TBPH in Q3 2019 and has held it in 3 quarters since. The position peaked at $2.52M in Q3 2019. 125 funds tracked by Wall St. Rank hold TBPH as of Q2 2020.

361 Capital held 32,680 shares of Theravance Biopharma worth $686K as of Q2 2020.
361 Capital sold 5,074 Theravance Biopharma shares in Q2 2020, an estimated $130K.
Theravance Biopharma made up 0.32% of 361 Capital's portfolio in Q2 2020, its #165 holding.
361 Capital first reported a position in Theravance Biopharma in Q3 2019 and has held it in 3 quarters since.
361 Capital's Theravance Biopharma position peaked at $2.52M in Q3 2019.
125 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.